An Integrated Mass-Spectrometry Pipeline Identifies Novel Protein Coding-Regions in the Human Genome by Bitton, DA et al.
An Integrated Mass-Spectrometry Pipeline Identifies
Novel Protein Coding-Regions in the Human Genome
Danny A. Bitton1, Duncan L. Smith2, Yvonne Connolly2, Paul J. Scutt1, Crispin J. Miller1*
1Applied Computational Biology and Bioinformatics Group, Cancer Research UK, Paterson Institute for Cancer Research, The University of Manchester, Manchester,
United Kingdom, 2 Biological Mass Spectrometry Facility, Cancer Research UK, Paterson Institute for Cancer Research, The University of Manchester, Manchester, United
Kingdom
Abstract
Background: Most protein mass spectrometry (MS) experiments rely on searches against a database of known or predicted
proteins, limiting their ability as a gene discovery tool.
Results: Using a search against an in silico translation of the entire human genome, combined with a series of annotation
filters, we identified 346 putative novel peptides [False Discovery Rate (FDR),5%] in a MS dataset derived from two human
breast epithelial cell lines. A subset of these were then successfully validated by a different MS technique. Two of these
correspond to novel isoforms of Heterogeneous Ribonuclear Proteins, while the rest correspond to novel loci.
Conclusions: MS technology can be used for ab initio gene discovery in human data, which, since it is based on different
underlying assumptions, identifies protein-coding genes not found by other techniques. As MS technology continues to
evolve, such approaches will become increasingly powerful.
Citation: Bitton DA, Smith DL, Connolly Y, Scutt PJ, Miller CJ (2010) An Integrated Mass-Spectrometry Pipeline Identifies Novel Protein Coding-Regions in the
Human Genome. PLoS ONE 5(1): e8949. doi:10.1371/journal.pone.0008949
Editor: Rodolfo Aramayo, Texas A&M University, United States of America
Received November 12, 2009; Accepted January 6, 2010; Published January 28, 2010
Copyright:  2010 Bitton et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This project was funded by Cancer Research UK. The funders had no role in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: cmiller@picr.man.ac.uk
Introduction
Since its release in 2001, the draft sequence of the human
genome [1] has been revised numerous times and genome
annotation continues to evolve [2]. Even so, the total number of
genes is still unknown, and the estimated number (20,000–25,000)
remains in dispute [3–7]. This lack of a definitive catalogue applies
not only to genome databases, but also to the secondary protein
and transcript databases upon which so many molecular biology
assays are based. For example, mass spectrometry techniques that
rely on a search against a database of known proteins will fail to
identify previously unseen peptides, while the majority of
microarrays, which are designed against a database of known or
predicted transcripts, are unable to profile transcription that
occurs outside those regions for which their probes were designed.
With the advent of next generation sequencing [8,9], tiling
[6,10–13] and exon arrays [14], which feature probes targeting
many more speculative areas of the genome [15,16], numerous
studies have found evidence for transcription outside known or
predicted protein coding genes [6,10–13,17]. Much of this has
been attributed to novel non-coding RNA, such as miRNAs [18],
or to non-functional transcription, but, given the lack of a
definitive catalogue of all human proteins, it is likely that at least
some of this novel RNA is translated into previously unreported
proteins [19].
High throughput tandem mass spectrometry (MS/MS) has
become a favoured method for the identification of peptides and
their cognate proteins in a complex protein mixture [20–25]. Such
an approach normally leads to the production of thousands of
spectra, each corresponding to the ion signature of a peptide,
which are then identified using a database search algorithm such
as Sequest [21], Mascot [24], or ProteinPilot [26]. These programs
attempt to assign a peptide sequence to a spectrum, while ranking
and scoring each assignment, and all assume that the peptide/
protein exists in the database. This is a fundamental constraint
that restricts the analysis to known and predicted proteins, and
prohibits the discovery of novel coding regions.
A significant aspect of many proteomics experiments is the
existence of ‘orphan’ peptides, those that have an experimental
mass, but for which a sequence could not be assigned. A number
of groups [27–34] have hypothesized that some of these may be
due to the existence of novel protein sequences that are not
currently represented in the databases, and have attempted to
predict novel proteins by expanding the protein database used to
identify proteins by tandem Mass Spectrometry (MS/MS) by
translating the entire genome in all three forward and reverse
reading frames [27,28,31–34]. The approach accepts the genetic
code, but ignores the conventional signals of gene structure, such
as initiation codon and known exon/intron boundaries. In so
doing, more segments of the raw DNA sequence are represented
by putative translation products, allowing greater coverage.
However, two significant disadvantages are associated with this
technique. Firstly, the extended search requires a much larger
database of putative sequences, with a corresponding rise in the
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amount of time and space required to analyse the data, and
secondly, the extended database will also contain a large number
of spurious sequences, some of which may match the experimental
data by chance [22,31,32,35]. This magnifies the false positive
rate, making it difficult to distinguish real matches from chance
occurrences; already an issue with existing database searches.
Nevertheless, the approach has been applied successfully to plant
[27,28] and bacterial [34] genomes, allowing the detection of novel
coding regions, the confirmation of gene predictions and the
refinement of genome annotations. Recently, Tanner et al. [30]
generated an expanded repertoire of predicted proteins using
translations of EST and gene prediction data that were then used
successfully to identify novel loci in human, while Menon et al. [29]
were able to apply a similar approach in mouse. However, neither
considered an unbiased full translation of the entire genome, in part
because of the problem of controlling the False Discovery Rate
(FDR) resulting from analyses against larger genomes.
Here we describe a novel pipeline that employs a straightfor-
ward search against a six-frame translation of the human genome
(Figure 1). We were able to identify and confirm experimentally
that the pipeline does indeed identify novel proteins in high
throughput MS/MS data. The pipeline uses a concatenated
reverse database [36] to estimate the FDR and incorporates
filtering steps that target pseudogenes, repeat elements and
sequence conservation across genomes to find additional support
for the assignments made by the database search algorithm.
Database searching was performed by first generating the full 6-
frame translated database and an equivalent reverse decoy
database [36]. Since it was not possible to concatenate these two
databases and perform a single search, due to the amount of
memory required by the software [30], we instead split the data by
chromosome into 23 separate target and decoy databases. A series
of pre-screening searches was then conducted on each individual
database, to yield a set of target and decoy hits for each
chromosome. In this way non-matching peptides were identified
and eliminated from the analysis, making it possible to
dramatically reduce the search space. Importantly, since decoy
hits are also considered at this stage, it is possible to perform this
data reduction step whilst preserving the information required for
a reliable estimation of the FDR.
All hits resulting from this initial search were then combined
with the Celera protein database to generate a single concatenated
resource containing all possible spectrum-matching target and
decoy peptides. All spectra were then searched for a second time
against this reduced database in order to allow peptide
assignments to be performed in the presence of other, competing,
Figure 1. A pipeline to identify peptides originating from uncharacterised proteins using LC MS/MS data. Data are subjected first to
identification using ProteinPilot and then filtered according to genome annotation. A subset of predicted novel peptides were then confirmed by
addition MS/MS.
doi:10.1371/journal.pone.0008949.g001
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sequences. This is necessary since some spectra that match well in
one chromosome may have a better match to a different sequence
on another chromosome. These occurrences cannot be identified
unless all candidate sequences are considered in a single batch.
Similarly, some peptides that match to the decoy database may
also have a better match to the target database. Again, this cannot
be considered unless decoy and target sequences are searched
together [36].
Candidate novel peptides resulting from this second search were
then taken through for further analysis and validation, and the
FDR estimated using the relative proportion of target and decoy
hits, as previously described [36–38].
Results
We evaluated the pipeline by applying it to a dataset produced
using two human cell lines, MCF7 and MCF10A, a breast cancer
and a non-tumourigenic epithelial cell line, respectively. Following
sample preparation and processing, the resultant MS/MS data
were searched once against the Celera protein database [39], and
once against our novel six-frame translation database, using
ProteinPilot.
6-Frame Proteogenomics Predicts Additional Protein
Coding Loci in the Human Genome
Of the 8,349 putative hits identified following the pre-screening
search, 4,603 were shared with the Celera database peptides
(6,219), displaying 74% correspondence at the peptide level
between the two database searches (Table 1). A total of 1,616
peptides found by the Celera search could not be identified using
the initial six-frame searches, but, as expected, a considerable
fraction of these (1,110) were found to span exon junctions (see
methods), and a further 167 were assigned by the six-frame search,
but were assigned a confidence of less than 95% by ProteinPilot.
When these 1,277 peptides are accounted for, correspondence at
the peptide level increases to 94.54%.
A total of 3,746 matches with no high-confidence Celera
equivalent were identified in the six-frame search. Of these, 119
matched to multiple sites in the putative translated genome, and
85 were found to have low confidence (,95%) matches in the
Celera search. Both these sets of peptides were excluded from
further analysis, leaving 3,542 peptide sequences (3,503 six-frame
accessions) for further examination.
In the second database search, the full 118,184 MS/MS spectra
were then compared to a single amalgamated database containing
all Celera database entries (187,748), the 3,503 putative novel
protein sequences, and all possible decoy hit accessions (3,581).
Following this search, 3,162/3,542 putative novel peptides were
removed, leaving 380 peptides, identified with .=95% confi-
dence at a FDR of 4.97% (estimated using the reverse decoy hits
[40]). Only these peptides were considered further.
These 380 peptides were then positioned relative to known
genes using X:Map, a genome annotation database [41]. Peptides
were classified as ‘intergenic’ (279 peptides), ‘intronic’ (53), and
‘exonic’ (48), based on their location relative to known protein
coding features, as defined by Ensembl (version 47) [42]. Each
exon is associated with a reading frame in which translation is
expected to occur. Exonic peptides were further characterized as
‘in-frame’ when they occurred in the annotated reading frame
(34), and ‘not in-frame’ when they matched the genome within an
exon, but in a different reading frame to that annotated (9).
Generally, ‘in frame’ peptides correspond to matches against
known proteins, and are therefore of less interest when searching
for novelty; they were not investigated further here. Finally,
peptides found to extend the 39 or 59 ends (2 and 3, respectively) of
an exon were labelled ‘exon-extending’ (Table 2).
Putative novel peptides were then subjected to a set of filters
based on the location of repeat regions, pseudogenes and areas
with high evolutionary conservation score (computed using GERP
scoring across 10 species [43]). Peptides originating from more
highly conserved regions that were annotated neither as repeat
regions nor as pseudogenes were considered to be more likely to be
biologically relevant (122 peptides).
Confirmation of Proteogenomic Predictions by
Comparison with Synthetic Peptide Spectra
When only 99% confidence peptides are considered, 63 are
found by the pipeline (FDR: 2.7%). A subset of these (highest-
confidence) peptides was selected for experimental validation. An
underlying principle of protein MS is the assumption that under
the same conditions the same peptide should fragment in a similar
way, and thus yield a similar ion spectrum. The fragmentation
pattern of a synthetic peptide should therefore be highly similar to
that of a ‘‘real’’ peptide with the same sequence, making it possible
to use synthetic peptides as a source of validatory spectra when
seeking confirmation of a peptide assignment by MS/MS. Many
of the spectra derived from complex mixtures feature ions that are
not accounted for by the best sequence match. Often these are the
result of the fragmentation of two different precursors simulta-
neously, leading to the production of chimeric spectra. Fragment
ions that were carried over from a previous collision, background
ions and/or inorganic compounds can also lead to additional
peaks. When a single peptide is synthesized and analysed by MS/
MS, its spectrum is less likely to contain these additional ions. In
Table 1. Summary of the results obtained from LC-MS/MS analysis of the MCF7 and MCF10A cell lines.
Search/Level
Peptides .=95%
confidence
Peptides .=99%
confidence
Peptides .=0%
confidence
Spectra .=0%
confidence
% of spectra
analysed
Celera 6,219 (FDR = 0.19%) 5,537 (FDR= 0.11%) 14,204 65,896 55.75
Six-frame 8,349 (FDR = 40.03%) 5,316 (FDR= 19.04%) 33,066 63,451 53.68
Overlap 4,603 4,048 6,983 50,694 N/A
Celera unique 1,616 1,489 7,221 15,202 N/A
Six-frame unique 3,746 1,268 26,083 12,757 N/A
Results of the initial pre-screening search in which all 118,184 spectra were searched against the individual chromosome specific six-frame databases and associated
decoy databases. Data were also searched separately against the Celera database using ProteinPilot (ABI). For all searches FDR was estimated using the reverse decoy
hits, as described in the methods.
doi:10.1371/journal.pone.0008949.t001
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addition, post-translational modifications (PTMs) can also change
the fragmentation pattern of a given peptide. 8 peptides for
additional MS/MS validation, plus 2 positive controls, were
chosen, by manual inspection of their spectra, to minimise these
issues.
Synthetic peptides with the same sequences as the candidates
were produced and subjected to MS/MS analysis in the usual way.
7 out of 8 of the synthetic peptides (plus both positive controls)
were identified, at 99% confidence, with the same sequences as the
‘‘real’’ peptides, when searched using ProteinPilot against the
augmented database. An additional comparison between the real
and synthetic peptides, in which the number of common ions was
used as a metric of similarity was also performed. FDR was
determined empirically using a search of random, unrelated
spectra (see methods), providing an estimate of the likelihood of a
similar set of matches occurring by chance (Figure S1). At a 5%
FDR, corresponding to a score threshold of 34.6, the same 7
sequences were found to be similar to their synthetic counterparts,
along with both positive controls (Figures S1,S2).
Two of these 7 peptide sequences had high sequence similarity
(BLAST [44]) to 2 distinct forms of Heterogeneous nuclear
ribonucleoproteins [HNRNPL and HNRNPA1 like, chromosome
19 and 2, respectively (Table 3)]. HNRNPs play a major role in
the packaging, processing, transporting and function of mRNA
[45] as well as the modulation of splice site selection. One of these
peptides (Peptide 3; Table 3 QPPLLGDHPAEYGEGR), also
confirmed at the transcript level by RT-PCR (Figure S3), extends
the 39 end of exon 7 (ENSE00000704494) in HNRNPL,
contributing an additional 3 amino acids to the protein sequence
(Figure 2). Note that these additional 3 amino acids also provide
the appropriate terminal arginine required for enzymatic cleavage
by trypsin; the shorter form of the peptide would not have been
identified. This exact peptide sequence was found to exist in both
mouse and rat protein homologues, and alignments of these
sequences found that the specified intron is retained in both
organisms, encoding an additional 37 additional amino acids
(Figure 2).
The second peptide (Peptide 5; Table 3) fell within a region
showing sequence similarity to HNRNPA1 (Table 2). This peptide
prediction is located within a regional Genscan [46] (Figure 3),
suggesting an open reading frame at this locus. A BLAST search
and 3D homology modelling analysis predicts that the region
encodes 271 amino acids (3 exons) that include the RNA binding
domains necessary for a functional HNRNPA1 like protein (Figure
S4), and transcript expression at this locus was again confirmed by
RT-PCR. This second peptide was pseudo-tryptic (i.e.
SSGLYGGGGQSFDKP), and the known HNRNPA1 protein
was also identified in this dataset (ROA1_HUMAN), and a similar
peptide sequence (SSGPYGGGGQYFAKPR) also contributed to
the identification of ROA1_HUMAN. Given the similarity
between both sequences it might appear at first sight as though
the novel peptide might be erroneous. However, even though both
Table 2. Pipeline predictions.
Peptide classification
Peptides .=95%
(2nd search)
Pseudogene
filter
Repeat
filter
Conservation
SR.=0
.=99%
confidence cutoff
Peptides
synthesized
Intergenic 279 269 157 101 56 7
Intronic 53 53 30 15 2 0
Exonic ‘Not in Frame’ 9 8 7 3 3 0
Exonic ‘Extending’ 5 4 3 3 2 1
Total 346 334 197 122 63 8
All 118,184 spectra were searched against a concatenated database comprising all Celera accessions, target and decoy hits from the pre-screening search (Table 1).
Peptides that were uniquely identified by the six-frame search are referred as ‘orphan’ peptides. These peptides were classified according to their genomic position.
SR – averaged conserved GERP score for the region from which the peptide originated. FDR was computed using the reverse decoy hits, as described in the methods.
doi:10.1371/journal.pone.0008949.t002
Table 3. Pipeline predictions confirmed by comparisons to spectra obtained from synthetic peptides.
Peptide
classification Location Sequence
Max
common ions
Up/down
MCF10A
Conservation
SR
1 Positive control Chr:8 (21) 145066695–145066727 AGLVGPEFHEK 78 No 25.68
2 Positive control Chr:17 (+1) 77639940–77639975 DNLEFFLAGIGR 137 Down 33.06
3 Exonic extend Chr:19 (21) 44022955–44023004 QPPLLGDHPAEYGEGR 126 No 64.54
4 Intergenic Chr:3 (+1) 197481979–197482005 TQALVEILK 81 No 9.03
5 Intergenic Chr:2 (+1) 194761171–194761215 SSGLYGGGGQSFDKP 56 Down 0
6 Intergenic Chr:20 (21) 46619533–46619600 SLATFQGQFNSWAGGPGSFVER 103 No 0
7 Intergenic Chr:8 (+1) 21164240–21164278 TVGSRAATFVAGR 52 No 0
8 Intergenic Chr:17 (+1) 74766590–74766619 GAVPASLAPK 47 Up 0
9 Intergenic Chr:7 (+1) 43117591–43117632 GSVRKGLGTPSGIR 52 No 0
FDR calculated following 7,000 independent comparisons between a randomly chosen set of 10 different spectra (70,000 different spectra in total) and the synthetic
spectra (8,672). RT PCR-reverse transcriptase PCR; Up/down regulation in MCF10A/MCF7 cell lines was determined using iTRAQ reporters in two experimental and a
single control quantitation channels.
doi:10.1371/journal.pone.0008949.t003
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sequences are very similar, the database searches are performed by
comparing ion signatures, not amino acid sequences. It is thus
important to consider differences at the spectrum level, rather than
simply considering their alignments. A manual fragmentation
simulation of both peptide sequences shows that they would
produce very different fragmentation patterns (data not shown). In
addition, both peptides were independently identified (by different
spectra) in the database search, providing evidence in favour of
both their existence in the proteome. It is unlikely that this peptide
was simply an artefact.
The remaining 5 novel peptides (Table 3) displayed some weak
similarity (expectation value.1) to human peptides, raising the
possibility that some of the peptides could actually be explained by
polymorphisms. However, in all cases the alignments either
Figure 2. Location and nature of novel exon-39 extending peptide in HNRNPL. Top: Location of peptide relative to exons. (Blue rectangle:
gene; brown rectangles: transcripts; red/white rectangles: exons; red: coding, white: UTR). Bottom: alignment between NP_001128232.1 (hnRNPL
isoform a, Rattus norvegicus) and HNRPL_HUMAN , showing location of the candidate peptide, and the retained intron found in the rat, but not the
human, sequence.
doi:10.1371/journal.pone.0008949.g002
Figure 3. Location and nature of novel integenic peptide relative to Genscan prediction. Top: the peptide identified by the pipeline is
classified as intronic, but is within the Genscan prediction GENSCAN00000020420. Bottom: the predicted protein is similar to hnRNPA1
(RA1L3_HUMAN; BLAST; Expect = 1e233; 73% Identity).
doi:10.1371/journal.pone.0008949.g003
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featured multiple mismatches, gaps, or lacked the necessary tryptic
site(s) at the N or C termini. These differences would result in
significantly different ion signatures, again making it unlikely that
the matches are artefactual.
The lack of any strong similarity to known, well characterized,
proteins (although there is cross-species sequence conservation at
the DNA level) means that further characterization of these
peptides would need to be performed experimentally. Seeking
additional confirmation at the transcript level for these peptides is
more challenging than for the two peptides described above,
because the lack of additional data describing known or predicted
gene-structures makes it difficult to position primers appropriately.
Nevertheless, one of these sequences (Peptide 4; Table 3) was
pursued further by RT-PCR (Figure S3), and transcription at that
locus was again confirmed.
Discussion
The incompleteness of current protein databases acts as a
limiting factor when seeking novelty with MS/MS data. This can
be minimized by a search against all possible protein products,
generated by translating the entire genome in all reading frames,
but is hampered by the corresponding increase in the False
Discovery Rate, which makes it difficult to distinguish real events
from chance occurrences [36]. The FDR is further magnified if it
is necessary to search the target (and decoy) databases in batches,
since the same spectrum can be assigned multiple times to different
peptides. Here, for example, the FDR following the pre-screening
stage was estimated at ,40%, dropping to 5.0% following the
second database search; a consequence of the removal of 90% of
the candidate peptides by competition. Note that the shrinkage of
the database is not the reason for this drop, since all possible decoy
hits were included in the second search. This shows that it is
possible to perform useful 6-frame translated searches against the
entire human genome whilst controlling the FDR to reasonable
levels; further supported by the successful confirmation of a subset
of the candidate peptides by a different MS/MS approach.
We also considered using mRNA data to confirm the existence
of transcription at each putative locus of translation. Two
additional filters were applied based on Expressed Sequence Tag
(EST) data and Affymetrix Exon arrays (data not shown). The
former provides evidence that transcription has been previously
observed at a given location, while the latter arrays feature many
probesets targeting both EST predictions and those arising from in
silico methods such as Genscan [46]. These can then be used to
confirm transcription in mRNA samples paired with those
subjected to MS/MS. When exon array and EST filtering were
applied to the orphan peptide set, these two steps resulted in all but
one of the orphan peptides being rejected, including all 8 that were
taken through to experimental validation. This reflects the fact
that both exon arrays and ESTs remain biased towards the better
characterized (and, generally, protein coding) regions of the
genome. As an extra validation step, we therefore used RT-PCR
to confirm transcription for a subset of peptides, but this is not
scalable across a large dataset. Clearly, technologies such as tiling
arrays or next-generation sequencing may be used to provide a
more global assessment of transcription [47], but since a
substantial proportion of the human genome is now thought to
be transcribed, these data may not prove to be particularly
discriminatory. Additional resources might therefore be better
directed at downstream validation, rather than further upstream
filtering, or at increasing the coverage of the MS/MS data, since
even if transcription is found at a given locus, this not conclusive
evidence of translation.
Current mass spectrometry techniques are unable to resolve all
proteins in a complex mixture, such as that arising from higher
eukaryotic cells, and are biased towards high abundance peptides
[48]. A recent meta-analysis of 2D proteomic data performed by
Petrak et al. [49] revealed that similar lists of differentially
expressed proteins are repeatedly reported by different research-
ers, regardless of the underlying experimental conditions, and
similar concerns have also been voiced with respect to LC-MS/
MS analyses, despite the greater proteome coverage that they offer
[50,51]. Thus, even though the dataset described here is likely to
contain mostly high abundance, housekeeping proteins, we
successfully identified and validated a novel isoform, a new gene
paralogue and five putative novel coding regions, and predicted
many more with high statistical significance. Given not only the
stringency of the pipeline but also the cutoffs chosen for the
validation by synthetic peptide, it is likely that the majority of these
other peptides predicted by the analysis pipeline may also be real.
These results are also interesting because the first dogma of
molecular biology – that DNA makes RNA makes protein – has
dominated in the methodologies used to identify novel proteins,
which are almost always inferred from known or predicted gene or
transcript sequences. Advances in mass spectrometry offer an
alternate route, in which novel genes can instead be inferred
directly from experimental evidence at the peptide level. This
relies on a different set of hypotheses and assumptions, and thus a
different pattern of true and false positives. With stringent filters
and appropriate validation, our methods successfully identify novel
proteins that are not found using conventional techniques. As
technology continues to improve, allowing the detection of lower-
abundance peptides, such an approach will become increasingly
powerful.
Methods
Protein Preparation and iTRAQ Labelling
26106 cells were washed with PBS, centrifuged at 5006g for
5 minutes and the dried pellet lysed in 0.5 M triethylammonium
bicarbonate +0.05% (w/v) SDS. Protein was digested and iTRAQ
labelled as described previously [52]. Briefly, 100 mg protein in
20 ml was reduced with 2 ml 50 mM tris-(2-carboxyethyl)-phosphine
(TCEP) at 60uC for one hour and then alkylated with 1 ml of
200 mM methylmethanethiosulphate (MMTS) in isopropanol at
room temperature for 10 minutes. Protein was digested by addition
of 10 ml trypsin at 0.5 mg/ml and incubated at 37uC overnight. One
unit of iTRAQ reagent (Applied Biosystems, Warrington, UK) was
thawed and reconstituted in 70 ml of ethanol, with vortexing for
1 minute. The reagent solution was added to the digest and
incubated at room temperature for one hour. Labelling reactions
were then pooled prior to analysis. Two technical replicates were
performed. MCF7 cells were labelled with 114 and 116 reporter
ions, MCF10A with 115 and 117. Both cell lines were obtained
from ATCC (LGC Standards, Middlesex, UK).
Liquid Chromatography and Mass Spectrometry
Pooled labelled peptides were analysed as previously described
[52]. Briefly, peptides were fractionated on an SCX cartridge
(Applied Biosystems) in 10 mM K2HPO4 (pH 2.7)+20% ACN,
with KCl concentration increasing in 50 mM steps from 50 mM
to 500 mM. Peptide fractions were dried, and re-suspended in
240 mL 2% v/v ACN/0.1% v/v formic acid. 60 mL was loaded
onto a 15cm reverse phase C18 column (75 mm i.d.) using an LC
Packings UltiMateTM pump and peptides separated on a 80 min
gradient from 5% to 40% v/v ACN/0.1% v/v formic acid on-line
to a QSTARH XL mass spectrometer.
Proteogenomics in Human
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Six-Frame Translation Database
The complete human genomic sequence (Homo_sapiens.
NCBI36.47) was translated in all reading frames. The translation
of the genomic DNA started from the first, second and third
nucleotide on each strand of each chromosome and ended
whenever a stop codon was encountered. Triplets were translated
according to the standard genetic code (IUPAC), to assign a one
letter symbol for each amino acid and a ‘*’ symbol for a stop codon.
A unique accession number that could be recognised by ProteinPilot
(e.g. 1P_HUMAN) was assigned to each protein sequence and the
genomic coordinates were recorded. Triplets containing ambiguity
codes (i.e. ‘N’, ‘H’, ‘R’ etc.) were ignored, as were sequences shorter
than six amino acids in length, and those which did not contain
Arginine (R) or Lysine (K) (R and K not followed by Proline are the
trypsin cleavage sites). Chromosome Y was not included (i.e. breast
cancer cell lines). A total of 170,642,968 putative proteins were
generated using Ensembl release 47.
Relative Quantification and Peptide Assignments
iTRAQ data analysis and peptide/protein database searches
were performed using ProteinPilot (version 2.0, Applied Biosys-
tems, Warrington, UK). The uninterpreted spectra (118,184) were
searched once against the human Celera protein database:
human_KBMS5.0.20050302.fasta (187,748 proteins), and once
against the six-frame database (one chromosome at a time). Only
peptide matches with a confidence.=95% were considered. The
proteolytic cleavage was set to trypsin and the program was
configured to report methylmethanethiosulphate (MMTS) as a
fixed modification.
Identification of Orphan Peptides
The list of Celera .=95% confidence peptides that contrib-
uted to the protein identification (contribution.0) were compared
to the complete list of the six-frame (regardless of their confidence/
contribution), and vice versa. This accounts for cases when a given
peptide sequence was assigned in both searches but the percentage
confidence was different. Only exact matches were considered and
isoforms, sequence differences between databases, polymorphism
etc., were not included. A similar comparison based on the spectra
rather than on peptides was also performed.
Celera Peptide Mappings
The list of Celera peptides was locally BLAST searched (–M
PAM30 –e 100 –W 2) against the human Ensembl [42] peptide
database (Homo_sapiens.NCBI36.47.pep.all.fa) in order to re-
trieve Ensembl transcript IDs. This approach indirectly compares
the Celera and the Ensembl databases. Minor discrepancies
between the two databases therefore resulted in a small number of
peptides not being mapped. The high e-value set for the BLAST
search ensured that almost all possible hits were obtained.
Nevertheless, only exact peptide matches of the same length as
the query length were extracted. Finally, a BioPerl Ensembl API
script [53] was used to pull out the peptides’ genomic coordinates.
For peptides located within exon-exon junctions, two sets of
coordinates were retrieved. Similarly, a peptide sequence that
exists in more than one place in the genome (e.g. shared between
protein families), would also have more than one set of
coordinates. These ‘multi-target’ peptides were excluded from
further analysis.
Mapping of the Six-Frame Peptides
In order to retrieve the exact genomic coordinates of the six-
frame peptides, the parent putative proteins (ORFs) were retrieved
from the six-frame database using fastacmd accompanied by the
six-frame unique ID. Since the genomic coordinates were initially
recorded during the database construction, it was possible to
calculate the exact genomic position of the peptides simply by
positioning the peptide sequences within their parent protein
sequences. The BioPerl and Ensembl API script were also to
confirm the exact location of the peptides, as described above.
This accounts for cases when ProteinPilot assigned more than one
unique accession to a given peptide (i.e. mapped to more than one
place in the genome).
The Exon Junction Database
The database was constructed using a list of all protein coding
transcripts, as retrieved from X:Map. The exon sequences, along
with the coordinates of their transcripts were retrieved. The 59 and
the 39 sequence ends (54bp) of the exons were extracted,
concatenated, shuffled and translated in three frames (the strand is
known), so as to include all possible splice variants junctions. In cases
where the exon ends were shorter than 54 bp the entire exon
sequence was included. In addition, for 59-terminal exons, only 39
ends were used, whereas for 39-terminal exons the 59 ends were used.
Analysis of Celera Unique Peptides
A considerable fraction of Celera peptides could not be
identified by the search against the six-frame database. These
were mapped back to their genomic coordinates, as before, while
junction peptides were identified if two sets of coordinates were
retrieved (in the same locus), or if they perfectly matched exon-
junction database entries, following a BLAST search.
Positioning & Grouping of Six-Frame Unique Peptides
‘Orphan’ peptides were positioned within the genome structure
and classified according to their location using the exonmap
library [41] in R/BioConductor. The exonmap R package
supports a series of queries that enable direct mapping between
probesets, exons, genes and transcripts to be made. The peptide
coordinates were used to querying X:Map as follows: Firstly, each
set of coordinates was used to search for a gene that may be found
within its range. Secondly, each set of coordinates was used to
search for an exon that may be found within its range. Then, the
differences between the two search results and the initial list were
identified, allowing peptides to be classified as exonic, intronic and
intergenic. The ‘multi-targeted’ peptides were excluded from
further analysis.
Exonic peptides were allocated to three subgroups (‘In-Frame’,
‘Not in frame’, ‘Extending’), based on whether they occur on the
same frame as the exon from which they were originated (based on
whether the peptide could be positioned within the translated
transcript), or alternatively whether they extend their correspond-
ing exon coordinates based comparison, Perl script).
Pseudogene Filtering
The peptide’s genomic sequences were retrieved using a BioPerl
Ensembl API script. Thereafter, these sequences were BLAST
searched against the manually curated human cDNA pseudogene
database (Homo_sapiens_VEGA_jan_cdna_pseudo.fa, download-
ed from ftp://ftp.sanger.ac.uk/pub/vega/). Only exact matches
(peptides with 100% identity, same length, and same strand as the
query sequence) were filtered out.
Microarray Data Analysis
Briefly, 6 CEL files representing 6 chips (3 MCF7 and 3
MCF10A) were analysed. All analyses were performed using
Proteogenomics in Human
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BioConductor/R [54] and the stored procedures found in the
exonmap package , as described in [14]. Raw expression data
were processed in R using the ‘affy’ BioConductor library.
Expression summarisation was performed using RMA [55] with
chip definitions supplied via a custom CDF file, as described in
[14]. All data have been submitted to GEO (accession:
GSE19154).
EST Evidence
The peptide’s genomic sequences were retrieved as above and
BLAST searched against the human EST database (human_est.
fasta, downloaded from ftp://ftp.ncbi.nlm.nih.gov/BLAST/db/
FASTA/). Only exact matches (peptides with 100% identity,
same length, and same strand as the query sequence) were
retained.
Repeat Region Filtering
The peptides’ genomic coordinates were used to query the
Ensembl API in order to exclude peptides that originated from
repetitive regions.
Conservation Across 10 Species
The peptides genomic coordinates were used to query the
Ensembl API in order to assess the conservation of the peptides
among different species (human, chimp, rhesus, cow, dog,
mouse, rat, opossum, platypus, and chicken). Ensembl provides
a nucleotide level GERP (Genomic Evolutionary Rate Profiling)
scoring [43], that reflects the amount of inferred substitution,
which in turn allows the identification of constrained elements.
The substitution rate for each nucleotide was calculated as
R=S(Expected-Observed) and a SR (sum of scores across the
peptide) was calculated for each peptide and divided by its
length. If scoring at that region was not available, R was
reported as 0 and therefore SR= 0, while a positive SR should
be expected in conserved regions and vice versa. In order to
choose an appropriate cutoff value, 5,537 real exonic (Celera
peptides with .99% confidence, FDR= 0.11%) and the
‘intergenic’ group of six-frame peptides (1,441 peptides with
.99% confidence and FDR= 19.04%) were assessed and both
distributions of SR values were plotted (all SR= 0 were
removed). A non-parametric test (Wilcox rank sum test,
wilcox.test command, R package) was performed to examine
whether there was a difference between the two distributions,
and a cutoff was chosen accordingly.
Reverse Database and False Discovery Rate Calculations
Reverse database searches were performed using the PSPEP
program [40] (Proteomics System Performance Evaluation
Pipeline, ABI) that operates together with ProteinPilot. Since
PSPEP estimates the false discovery rate within the concatenated
database rather than the FDR solely within the target database, we
estimated the FDRs under a given confidence threshold (95% &
99%) for each target database as discussed in [37,38] FDR= (False
positives/(False Positives + True Positives))*100 [37,38].
Second Database Search Against Modified Celera
Database
A database search was performed (settings as above) against a
modified Celera database that includes, all Celera database entries
(187,748), the 3,542 putative novel protein sequences (3,503
accessions) and all decoy hits reported by ProteinPilot (regardless
of their assigned confidence) following the pre-screening stage
(3,581 accessions).
Peptide Synthesis
Following re-identification of the putative novel peptides by the
second database search, a manual examination of the corre-
sponding 40 spectra was carried out. In total, 8 peptides were
chosen along with 2 positive controls and synthesized (Euro-
gentec, minimum of 5mg of each with .70% purity). The
peptides were iTRAQ labelled and subjected to LC-MS/MS
analysis using the same settings as before, leading to the
generation of 8,672 spectra.
Comparisons of Fragmentation Patterns
Both the synthetic (8,672) and the original 118,184 spectra
were converted to mgfs format (Mascot generic file) using
ProteinPilot. Thereafter, the 10 original spectra (8 putative
novel peptides and 2 positive controls) were extracted and
compared to the synthetic spectra (4,531 scores). Pairs were
scored by counting the number of common ions (excluding
iTRAQ ions and potential ammonium ions, m/z.160). In
order to generate random scores, 10 spectra (different from the
original 10 peptide sequences) were randomly chosen from a
pool of 118,105 spectra. This step was repeated 7,000 times
(without replacement). Therefore, 70,000 random spectra were
compared to the synthetic spectra (59.23% of the dataset),
generating 518,112 random similarity scores. This was then
used as a null distribution from which the FDR was calculated,
as in [56].
Homology Modelling and Structural Alignment
The protein sequence obtained from Genscan prediction
(GENSCAN00000020420) was used for homology modelling in
order to predict its 3D structure. This was performed using Swiss
model [57] (automated mode settings), followed by structural
alignment to its template using PyMOL [58].
Reverse Transcription PCR
Total RNA was isolated from MCF7 and MCF10a cells using
the Qiagen RNeasy kit (Qiagen, Sussex, UK). Genomic DNA was
digested using RNase-free DNase (Qiagen, Sussex, UK). Reverse
transcription was performed using Taqman reverse transcription
reagents (Applied Biosystems, Foster City, CA, USA). The
reaction included 1 mg total RNA, 2.5 mM random hexamers,
Taqman RT buffer, 5.5 mM Magnesium Chloride, 500 mM each
dNTP, 0.4 U/ml RNase inhibitor, 1.25 U/ml Multiscribe reverse
transcriptase and RNase-free water to a total volume of 100 ml.
The mixture was incubated at 25uC for 10 min, 48uC for 30 min
and 95uC for 5 min.
PCR was performed using 1 mM each primer, 100 ng cDNA,
100 mM each dNTP, 2.5 U Taq polymerase, polymerase buffer
and RNase-free water to a volume of 25 ml. Cycling conditions
included denaturation at 94uC for 5 min, 35 cycles of 1)
denaturation at 94uC for 30 sec 2) annealing at 60uC for 30 sec
and 3) extension at 72uC for 1 min, finishing with a final extension
of 72uC for 5 min. PCR fragments were resolved using the
MultiNA Microchip Electrophoresis System (Shimadzu Biotech,
Milton Keynes, UK).
Primer sequences: Control set (Left -TCCTCAAGTTTCCG-
CACAGT Right- GGCTGCCCATTTTGTATTGA, Product
size - 82), Peptide 5 set (Left –TCAGTGGTCTTGGTGGCTTT,
Right – CCACCATAGAGGCCAGAACT, Product size – 208),
Peptide 3 set (Left – GCAGCAACCCCAACAAAC, Right –
CCCTGCCCTCACCATATTCT, Product size – 75), Peptide 4
set (Left – CATTGGGGTGGGAAAAAGTT, Right – GGC-
CATTGTTGCACAGAGAG, Product size – 187).
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Supporting Information
Figure S1 Comparison between real and random spectra pairs.
A) The distribution of the number of matching ions between
random pairs (red, 518,112 scores) and ‘‘real’’ pairs (blue, 4,531
scores). The locations of the spectra identified in this assay are
indicated by their reference number in table 3; two positive
controls (1–2) and all putative novel peptides (3–9). B) The
calculated FDR against the number of matching ions between
spectra pairs.
Found at: doi:10.1371/journal.pone.0008949.s001 (0.13 MB TIF)
Figure S2 Comparison between real and synthetic peptide
sequences. Spectra from real (top) and synthetic peptides (bottom)
for two positive controls (1–2) and all putative novel peptides (3–9)
Found at: doi:10.1371/journal.pone.0008949.s002 (1.22 MB TIF)
Figure S3 Reverse Transcription PCR confirms transcript
expression at loci corresponding to novel peptides. Primer sets
specific to peptides 3, 4, 5, Table 3, were used to positively identify
gene transcription by RT-PCR. The ribosomal protein L14
(RL14_HUMAN) was used as a positive control. Reverse
transcription reactions were also performed in the absence of
reverse transcriptase (RT) to confirm complete DNase I digestion.
UM=Upper markers, LM=Lower markers. Expression for all
targets was confirmed in MCF10A, while transcription for peptide
5 was inconclusive in MCF7.
Found at: doi:10.1371/journal.pone.0008949.s003 (0.25 MB TIF)
Figure S4 3D structure of putative novel protein sequence.
Protein sequence of GENSCAN00000020420 superimposed to
crystal structure of UP1 complexed with D(TTAGGGT-
TAG(2PR)G) a human telemoeric repeat containing 2-AMINO-
PURINE (gold, PDB Accession 1u1r; X-RAY, Resolution: 1.80);
Modelled by Swiss model server (Automated mode) [57].
Structures were superimposed using PyMOL.
Found at: doi:10.1371/journal.pone.0008949.s004 (0.59 MB TIF)
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